Why some of the most valuable innovations don’t come from new science, but from making existing science accessible to more people.
When most people hear the word innovation, they tend to think about something entirely new: a breakthrough technology, a scientific discovery, or a product capable of doing things that were previously impossible. Pharmaceutical executives might think about monoclonal antibodies, immuno-oncology, cell therapies, or mRNA platforms. In our minds, innovation is closely associated with scientific novelty and with pushing the frontier forward.
That is certainly one form of innovation. It is also the one that receives the most attention.
Years ago, I watched Nokia make what seemed like a curious strategic decision. At a time when most mobile phone manufacturers were competing to add color screens, cameras, internet connectivity, and increasingly sophisticated features, Nokia introduced a device that appeared to move in the opposite direction.
The Nokia 1100 was simple, inexpensive, and remarkably durable. It lacked many of the features that dominated technology advertising at the time, which made the strategy difficult to understand for those of us who assumed innovation meant adding more technology. Yet Nokia was solving a different problem. Rather than competing for existing users, the company was trying to make mobile communication accessible to millions of people who still did not own a phone.
At the time, many of us assumed the future belonged to increasingly sophisticated devices, and I certainly would not have predicted what happened next. Contrary to what many of us thought — myself included — the strategy proved far more successful than expected. More than 250 million units were eventually sold, making the Nokia 1100 the best-selling mobile phone in history. Looking back, what is most interesting about the story is not the device itself but the insight behind it. Nokia recognized that a large part of the market was not asking for more features. It was asking for affordability, reliability, and access.
The pharmaceutical industry tends to celebrate a different kind of story. We naturally focus on discovery. New targets, new mechanisms of action, and new therapeutic platforms dominate conference presentations, investor discussions, and industry headlines. Those achievements deserve the attention they receive. Without scientific discovery, there would be no industry to begin with.
Yet some of the most important advances in pharma have emerged from a different challenge altogether: not discovering new solutions, but finding ways to deliver existing solutions to far more people.
One of the clearest examples is oral rehydration therapy. From a scientific perspective, there is very little about a mixture of water, salts, and glucose that resembles what we normally call innovation. It does not require advanced manufacturing, sophisticated equipment, or cutting-edge biology. In fact, its simplicity is precisely what made it so powerful.
The science behind dehydration had been understood for decades. The challenge was creating a solution that could be produced inexpensively, distributed widely, and used effectively in environments where hospitals, specialists, and advanced medical infrastructure were often unavailable. Because it met those requirements, oral rehydration therapy became one of the most successful public health interventions in history, saving millions of lives around the world.
Vaccines offer another example. Scientific discovery created the opportunity, but discovery alone was never enough. Manufacturing capacity, distribution networks, cold-chain logistics, reimbursement systems, public policy, and large-scale immunization programs all played essential roles in translating scientific progress into population-level impact. After all, a vaccine sitting in a laboratory refrigerator saves no lives. The organizations that create the greatest impact are often those that excel not only at invention, but also at making innovation accessible at scale.
This perspective is sometimes underappreciated in our industry. Scientific breakthroughs tend to attract attention because they are visible and exciting. Accessibility, scalability, affordability, and adoption rarely generate the same enthusiasm, even though they frequently determine whether a therapy reaches its full potential.
As healthcare systems around the world face growing financial pressure, that distinction may become increasingly important. Future innovation is unlikely to come exclusively from laboratories. It may also emerge from manufacturing processes that lower costs, distribution models that improve access, digital tools that increase adherence, or operational improvements that make therapies easier to deliver and easier to receive.
For pharmaceutical leaders, this raises an important question. Are we paying enough attention to the innovations that improve accessibility, scalability, and adoption? Or are we so focused on discovering the next breakthrough that we overlook opportunities to create value from what already exists?
The Nokia 1100 became the best-selling phone in history not because it had the most features, but because it solved a problem that mattered to millions of people. Healthcare is undoubtedly more complex than consumer electronics, but the underlying lesson remains surprisingly relevant. Sometimes the greatest opportunity is not creating a better product. It is finding a way to make a valuable product available to far more people.
As healthcare systems around the world struggle with the cost of innovation, that idea may become increasingly important. In fact, it may be particularly relevant for our friends in the GLP-1 market.
